معرفی
Alastair Keen is a Research Fellow in the Drug Discovery Biology department at Monash University, Australia. His research focuses on molecular mechanisms of G protein-coupled receptors (GPCRs), adrenoceptors, and novel protein degradation strategies for therapeutic targeting. He is actively contributing to high-impact studies published in journals such as Nature and Nature Structural & Molecular Biology.
Research Interests: Dr Keen's work spans molecular pharmacology, structural biology, and drug discovery. His primary focus lies in understanding GPCR signaling pathways, including canonical and non-canonical mechanisms, and developing tools to modulate these receptors using targeted protein degradation. He also investigates hybrid membrane proteins and metastatic signaling factors like P-Rex1, which play critical roles in cancer progression.
Publication Trends: Over the past few years, his research has centered on advanced structural and functional analyses of key signaling proteins. The publications show a strong trend toward elucidating molecular architectures and regulatory mechanisms of GPCRs and related effectors, with implications for drug development and disease intervention. Topics include receptor activation, inhibition via bacterial toxins, and structural autoinhibition in metastatic proteins.
Scientific Awards:
- No specific awards or honors were mentioned in the provided text.
Advising and Grants:
- No information available about students supervised or grants received.
Labs and Teams: Dr Keen is part of the Drug Discovery Biology theme at Monash University, collaborating with leading researchers such as Professor Michelle L. Halls and Dr Andrew M. Ellisdon. His work involves structural biology, biochemical assays, and pharmacological characterization, likely conducted within a multidisciplinary research team focused on signaling pathways and therapeutic innovation.
